Study of new drug E2511 for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an investigational drug, E2511, in people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and how it affects the body, which may help slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have been diagnosed with mild cognitive impairment or mild Alzheimer's dementia.
- You have a study partner who spends at least 8 hours per week with you and can support you during the trial.
- You have evidence of amyloid buildup in the brain, shown by a blood test, spinal fluid test, or PET scan.
- You are willing to undergo spinal taps (lumbar punctures) and MRI scans.
- You are not currently taking certain Alzheimer's medications (cholinesterase inhibitors) and are willing to stop them before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.